Showing: 1 - 7 of 7 RESULTS

Genemod Raises $1.7M in Oversubscribed Seed Round to Drive the Next Generation of Medicine

SEATTLE, Oct. 13, 2020 /PRNewswire/ — Genemod, a software solution for life scientists that uses data automation to streamline and accelerate research, today announced a $1.7M seed funding round led by Defy.vc with added support by Omicron, Unpopular Ventures, Underdog Labs, and Canaan Partners Scout Fund. The funding will enable Genemod to now include a complimentary product management software alongside the company’s flagship life sciences inventory management service. The funding is a stepping stone to bring Genemod’s vision to life as the company solves the problems around data sharing for biotech companies allowing research to be repeatable and cures to be developed at a faster pace.

Genemod’s cloud-based solutions offer biotech companies the ability to maximize productivity and consolidate data sharing with one collaborative workspace. By streamlining inventory, experiment, application and data management, Genemod helps scientists conduct repeatable research and develop cures faster. Labs from nationally recognized institutions, including the University of Washington School of Medicine, the University of California, Berkeley and the National Institutes of Health rely on Genemod’s cloud-based solutions to accelerate life sciences research and drug discovery. Today’s funding will allow Genemod to grow its current headcount by 50 percent and expand its customer base beyond academic institutions and into small enterprises.

“While the life sciences industry is known for developing inventive solutions to some of the world’s biggest health problems, many scientists are working with manual, siloed and inefficient processes,” said Jacob Lee, CEO and co-founder, Genemod. “Genemod aims to make a scientist’s journey just as innovative as their destination, driving faster and more creative problem solving. Today’s funding will allow us to make a major step toward achieving this goal.”

Alongside the funding, Defy.vc will serve as a growth partner for Genemod, supporting the company as it works to roll out its product roadmap for the latter half of the year. Neil Sequeira, co-founder and managing director of Defy.vc, will join Genemod’s Board of Directors.

“It is crucial to invest in companies leveraging technology to provide software for scientists working on the frontlines of solving the world’s global health challenges,” said Neil Sequeira, co-founder and partner, Defy.vc, “our firm believes that investing in software companies like Genemod will create incredible value in a variety of ways and rapidly solve some of the biggest impediments facing research and discovery.”

Founded in 2018, Genemod was part of the first Launch Lab from Venture Out Startups a company that helps early-stage founders gain traction with their product by acting as a ‘Co-founder as-a-Service.’

About Genemod

Genemod helps biotech companies maximize productivity through cloud-based inventory and product management solutions that drive the next generation of therapies. Life scientists and researchers use Genemod to collaborate on research, inventory reagents and streamline workflows. Alongside some of the world’s leading biotech institutions, including the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Genemod’s long-term vision is to enable organizations to develop cures faster by offering technologically advanced, pre-clinical

One Tinley Park Hosts Blood Drive Due To Shortages From COVID-19

TINLEY PARK, IL — One Tinley Park is hosting a blood drive on Oct. 30, at Union Bar & Grill to help gather more blood during the COVID-19 pandemic. The blood drive is in partnership with Versiti Blood Center of Illinois.

According to the Red Cross, blood donations are facing a serious shortage of donations due to the pandemic. One Tinley Park said they are proud to team up with the blood center to provide a safe outlet for people to make a difference in the community.

“As blood banks face coronavirus-driven shortages, donating has never been more crucial. The COVID-19 crisis has led to a drastic reduction in blood donations,” the organization said.

One Tinley Park said its goal is to have around 23 donors sign-up for the event to meet their target of 18 pints of blood. The organization said they have about 30 appointment slots to try and get to their goal.

The organization said they have teamed up with Union Bar & Grill, 17821 80th Ave., for the blood drive, and that the restaurant has offered to give a 20% discount to all blood donors.

According to the website, Versiti is a fusion of donors, scientific curiosity, and precision medicine that recognize the gifts of blood and life are precious.

To sign up for an appointment for the blood drive, visit the appointment schedule on the Versiti Blood Center of Illinois website.

This article originally appeared on the Tinley Park Patch

Source Article

Doctors slam Trump’s drive to greet supporters outside Walter Reed hospital

  • In a video posted via Twitter on Sunday, Trump said he would “pay a little surprise to some of the great patriots that we have out on the street.”
  • Shortly thereafter, the presidential motorcade drove by the perimeter of the Walter Reed National Medical Center, with Trump seen through the window of an SUV wearing a face covering and waving to supporters.
  • “Traveling in a car with several staff members while still in isolation also poses a risk of infecting those other exposed passengers. There was no obvious justification for this action,” Michael Baker, an epidemiologist at the University of Otago in Wellington, New Zealand, told CNBC via email.



a passenger seat of a car: US President Trump waves from the back of a car outside of Walter Reed Medical Center in Bethesda, Maryland on Ocotber 4, 2020.


© Provided by CNBC
US President Trump waves from the back of a car outside of Walter Reed Medical Center in Bethesda, Maryland on Ocotber 4, 2020.

LONDON — President Donald Trump on Sunday briefly ventured outside Walter Reed hospital in a motorcade to greet cheering supporters, a move that doctors have condemned for flagrantly disregarding precautions designed to contain the spread of the coronavirus.

Trump, 74, has released a series of videos over the weekend to try to reassure voters that he is recovering after testing positive for Covid-19.

“It has been a very interesting journey. I’ve learned a lot about Covid,” Trump said in a video posted via Twitter on Sunday. The president also suggested he would “pay a little surprise to some of the great patriots that we have out on the street.”

Shortly thereafter, the presidential motorcade drove by the perimeter of the Walter Reed National Medical Center, with Trump seen through the window of an SUV wearing a face covering and waving to supporters.

Trump has repeatedly downplayed the threat of the pandemic, criticizing Democratic presidential nominee Joe Biden as recently as last week for wearing a protective mask, even as the virus has infected millions of people and resulted in the deaths of more than 200,000 Americans.

“Every single person in the vehicle during that completely unnecessary Presidential ‘drive-by’ just now has to be quarantined for 14 days. They might get sick. They may die. For political theater,” James Phillips, doctor of emergency medicine at George Washington University, and an attending physician at Walter Reed hospital, said via Twitter on Sunday.

“Commanded by Trump to put their lives at risk for theater. This is insanity,” he said.

In a second tweet, Phillips added the risk of Covid-19 transmission inside the car was “as high as it gets outside of medical procedures,” saying the presidential SUV was not only bullet proof but hermetically sealed against chemical attack.

“The irresponsibility is astounding. My thoughts are with the Secret Service forced to play,” Phillips said.

In response to the criticism, White House spokesman Judd Deere told the Associated Press that Trump’s trip outside the hospital “was cleared by the medical team as safe to do.”

Deere added precautions were taken, including the use of personal protective equipment, to protect the president, White House officials and Secret Service

Trump’s drive outside Walter Reed hospital criticized by Secret Service members, doctors

A growing number of Secret Service agents have been concerned about the president’s seeming indifference to the health risks they face when traveling with him in public, and a few reacted with outrage to the trip, asking how Trump’s desire to be seen outside of his hospital suite justified the jeopardy to agents protecting the president. The president’s coronavirus diagnosis has already brought new scrutiny to his lax approach to social distancing, as public health officials scramble to trace those he may have exposed at large in-person events.

“He’s not even pretending to care now,” said one agent after the president’s jaunt outside Walter Reed National Military Medical Center.

“Where are the adults?” said a former Secret Service member.

They spoke on the condition of anonymity out of fear of retribution.

White House spokesman Judd Deere defended the outing, telling reporters that “appropriate precautions were taken in the execution of this movement to protect the President and all those supporting it.” Deere said precautions included personal protective equipment, without providing further details, and added that the trip “was cleared by the medical team as safe to do.”

The White House did not immediately respond to questions from The Washington Post on Sunday night.

Trump wore a mask as he waved to a crowd from the back of his vehicle, after announcing that he would “pay a little surprise to some of the great patriots that we have out on the street.” But the face covering was little comfort to doctors, who took to Twitter to criticize the trip as irresponsible. Masks “help, but they are not an impenetrable force field,” tweeted Saad B. Omer, director of the Yale Institute for Global Health.

Among critics was a doctor affiliated with Walter Reed.

“Every single person in the vehicle during that completely unnecessary Presidential ‘drive-by’ just now has to be quarantined for 14 days,” tweeted James P. Phillips, who is also a professor at George Washington University. “They might get sick. They may die. For political theater. Commanded by Trump to put their lives at risk for theater. This is insanity.”

Phillips said the risk of viral transmission inside the car is “as high as it gets outside of medical procedures.” Jonathan Reiner, a professor of medicine and surgery at George Washington University, noted that people inside a hospital wear extensive protective gear — gowns, gloves, N95 masks and more — when they will be in close contact with a coronavirus patient such as Trump.

“By taking a joy ride outside Walter Reed the president is placing his Secret Service detail at grave risk,” he tweeted.

Trump had been irked that White House Chief of Staff Mark Meadows suggested he was not doing well as he fought the virus, according to campaign and White House officials.

“The president’s vitals over the last 24 hours were very concerning, and the next 48 hours will be critical in terms of his care,” Meadows said Saturday afternoon, in sharp contrast to doctors who offered rosy

Way to Go! New Hyde Park students hold virtual blood drive

Two students from New Hyde Park Memorial High School have been combating the shortage of blood because of the coronavirus outbreak.

Aarti Devjani and Preesha Mody, both seniors, coordinated a seven-week virtual blood drive through the New York Blood Center in which individuals could schedule appointments to give blood through the center’s website. The drive allowed participants to stay safe and socially distance while helping their community, the students said.

As of late September, about 35 people had donated blood to the students’ drive, which ends Oct. 15. The duo has also raised more than $3,600 for the center through a GoFundMe page.

“This idea started in the middle of quarantine when we realized no one’s going anywhere,” Mody said. “Then my dad actually sent me this article about how there’s a shortage of blood, so we though ‘let’s do something about it.'”

The students then spread the word through social media — including Facebook, Instagram and Snapchat — and hung flyers in “every grocery store that would let us,” Mody said.

Devjani and Mody are members of their school’s National Junior Honor Society, Science Honor Society and Science Olympiad Club. Devjani has also volunteered at NYU Winthrop Hospital in Mineola, and Mody has volunteered at Stamford Hospital in Connecticut.

— MICHAEL R. EBERT

Source Article

How The New Rapid Tests Could Drive A Coronavirus Testing Paradigm Shift : Shots

A new wave of rapid coronavirus tests have entered the market and have the potential to greatly expand screening for the virus.

Spencer Platt/Getty Images


hide caption

toggle caption

Spencer Platt/Getty Images

A new wave of rapid coronavirus tests have entered the market and have the potential to greatly expand screening for the virus.

Spencer Platt/Getty Images

A new generation of faster, cheaper coronavirus tests is starting to hit the market. And some experts say these technologies could finally give the U.S. the ability to adopt a new, more effective testing strategy.

“On the horizon — the not too distant horizon — there are a whole series of testing modalities coming on line,” says Dr. Ashish Jha, dean of the Brown School of Public Health. “And that gives us hope we can really expand our testing capacity in the nation.”

Until now, testing has been primarily used to diagnose people who may have COVID-19 and any of their close contacts who may also be infected. But a stubborn shortage of the molecular tests most commonly used — and slow turnaround time for results — has hobbled the nation’s ability to stop outbreaks and contain the pandemic.

That could change, argue Jha and other public health researchers, as new rapid tests — primarily antigen tests — become more widely available, enabling communities to start widespread screening of the highest-risk people.

“It is a paradigm shift,” Jha says. “What I think new testing capacity allows us to do is actually play offense — go and hunt for the disease before it spreads to identify asymptomatic people before they spread it to others. It really becomes about preventing outbreaks — not just capturing them after they’ve occurred.”

Jha and a team at the Harvard Global Health Institute have periodically evaluated how much testing the country and individual states need to effectively fight the spread of the virus.

In a new analysis the group completed for NPR, researchers developed daily testing targets, showing what would be needed to routinely screen large numbers of asymptomatic people. The researchers factored in the growing availability of the rapid coronavirus tests.

The U.S. would need 4.4 million tests every day, the analysis concludes, to reach what Jha calls “a basic level of proactive testing.” The idea is to do regular testing of some of the highest risk groups — stopping outbreaks before they can spill over to the rest of the community.

This scenario calls for screening all nursing home residents and staff twice a week and weekly testing of every prison inmate and guard, firefighter, police officer and emergency medical technician, as well as teachers and staff in K-12 schools, and all university students.

Using the older molecular test technology, the U.S. has never managed to perform more than about 1 million tests per day. But the companies that make the new antigen tests are ramping up production and additional tests are in the pipeline. As a result, Jha and others estimate that there could be enough

Organoids Market: Growing Concerns about Systematic Treatment Solutions for Personalised Medicine to Drive the Market Growth

Global Organoids Market: An Overview

The global organoids Market is a fragmented landscape with several new players driving intense competition and rising investment in innovation. Recent advancements in Big Data, and technologies like 3D printing have opened up new skies of growth for innovation.

Organoids is a simplified and compact version of organs which depicts micro-anatomy realistically. These are usually made up of stem cells, tissues, or pluripotent stem cells. These can organize themselves in three-dimensions, which is key to its realistic representation of organism.

In 2013, the scientific community named the development in organoids as one of the biggest scientific achievement in recent times. This is not surprising as understanding real-movements of organs allows scientists to study various abnormal as well as healthy behaviour in cells, and test new drugs to bring forth solutions to challenges such as Alzheimer’s disease which are yet to be completely understood. Technologies like Big Data promise to a rapid progress in understanding cells, while 3D printing promises more realistic, and more diversification in materials used for research.

Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73363

Global Organoids Market: Trends and Opportunities

A new study published in the National Institutes of Health Journal shows that La Crosse Virus or LACV can cause inflammation of the brain in children. The study also shows that at different stages of development cycle, the cells affect children differently. The study relied on the use of organoids for the understanding the primary function of brain cells in the nervous cell system. The study and rising concerns about neurons causal relationship with LACV promise new research opportunities for end-players.

Rise in chronic diseases including most forms of cancer, and new little understood major illnesses like Alzheimer’s have rung many alarm bells in the healthcare sector. Additionally, the cost of treatment for many of these diseases remains extremely high and out of reach for many patients.

The rising population of elderly, increased investment in research for chronic illnesses, and growing burden on healthcare system are expected to drive more capital towards research and innovation. Moreover, advancements in organoids replacing conventional 2D cells with a 3D model promises new growth opportunities for researchers in return. Growing concerns about systematic treatment solutions for personalised medicine will also drive new opportunities for growth in the organoids market.

Request for Analysis of COVID-19 Impact on Organoids Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73363

Global Organoids Market: Regional Outlook

The global organoids market report covers all regions including North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Among these, the North American region is likely to post highest revenues, thanks to increasing technological adoption of big data, and faster streamlining process by the FDA.  The new drive to innovation in the industry is a major trend in the region as old patents expire, and new opportunities due to a bigger push by the regulatory environment drives growth in the region. The global organoids market is also expected to register robust growth in Asia Pacific, as increasing private investments for